BRD4

Across TCGA pan-cancer cohorts, BRD4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BRD4 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher BRD4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BRD4 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

HNSC, LUAD, and LSCC are the cancer types where BRD4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	IV	0.547	0.973	<.001	74	view →
LUAD	DFS	Tertile	All	0.816	0.553	.015	5	view →
LSCC	DFS	Median	II,III,IV	0.999	0.858	.026	3	view →
PDAC	OS	Median	II,III,IV	0.450	0.599	.022	2	view →
CCRCC	OS	Median	II,III,IV	0.917	0.777	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BRD4–HNSC (DFS)

Open the HNSC breakdown →